Madelaine Tully, MD
Family Medicine · Milwaukee, WINPI 1255419784
Payments from drug & device makers
Across 152 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$527
- Pfizer$382
- AstraZeneca$231
- Vanda Pharmaceuticals Inc.$155
- Aimmune Therapeutics, Inc.$121
- Bayer$120
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,787100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $527 |
| Pfizer | 20 | $382 |
| AstraZeneca | 12 | $231 |
| Vanda Pharmaceuticals Inc. | 7 | $155 |
| Aimmune Therapeutics, Inc. | 6 | $121 |
| Bayer | 5 | $120 |
| Lilly USA, LLC | 6 | $111 |
| Novo Nordisk | 7 | $108 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $101 |
| GSK | 7 | $101 |
| Astellas Pharma US Inc | 4 | $99 |
| Otsuka America Pharmaceutical, Inc. | 5 | $88 |
| Gilead | 4 | $70 |
| Exact Sciences | 3 | $70 |
| Boehringer Ingelheim | 3 | $47 |
| Viiv Healthcare Company | 3 | $46 |
| Sumitomo Pharma America, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $42 |
| Roche Diagnostics Corporation | 3 | $36 |
| Lundbeck LLC | 2 | $35 |
| Novartis | 2 | $35 |
| Alkermes, Inc. | 1 | $25 |
| Sanofi Pasteur Inc. | 2 | $24 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Nestle Healthcare Nutrition Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Seqirus USA Inc | 1 | $17 |
| Merck | 1 | $15 |
| Ardelyx, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
How this compares
$2,787 in reported general payments places this provider in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 126 | $142,752 |
| TrulicityDulaglutide | 60 | $80,988 |
| LinzessLinaclotide | 111 | $80,500 |
| MounjaroTirzepatide | 57 | $66,865 |
| JanuviaSitagliptin Phosphate | 46 | $66,312 |
| JardianceEmpagliflozin | 52 | $52,336 |
| TradjentaLinagliptin | 49 | $45,838 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 16 | $42,845 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $42,130 |
| EliquisApixaban | 34 | $41,117 |
| FarxigaDapagliflozin Propanediol | 29 | $39,334 |
| MyrbetriqMirabegron | 41 | $29,078 |
| EntrestoSacubitril/Valsartan | 17 | $22,479 |
| Breo ElliptaFluticasone/Vilanterol | 44 | $18,396 |
| Spiriva HandihalerTiotropium Bromide | 20 | $16,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $111 | $147,853117 claims |
| Novo NordiskOzempic | $108 | $142,752126 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $47 | $103,588112 claims |
| MerckJanuvia, Janumet | $15 | $80,90561 claims |
| AbbVieLinzess | $527 | $80,500111 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $101 | $67,055121 claims |
| AstraZenecaFarxiga, Symbicort | $231 | $49,43264 claims |
| PfizerEliquis | $382 | $41,11734 claims |
| Astellas Pharma US IncMyrbetriq | $99 | $29,07841 claims |
| NovartisEntresto | $35 | $22,47917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,482 family medicine providers in Wisconsin.
Other family medicine in Milwaukee
- William PalinMilwaukee$693K
- Mario KapetsonisMilwaukee$123K
- Syed AhmedMilwaukee$78K
- Steven BondowMilwaukee$34K
- Suresh MisraMilwaukee$16K
- Ramneet BhathalMilwaukee$12K
- Roland WillockMilwaukee$7K
- Taha El-ShahatMadison$15.6M
- Jonathan MeimanMadison$4.3M
- John AgaibyKenosha$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.